Search Results - "Sanoff, Hanna K."

Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk by Burd, Christin E, Jeck, William R, Liu, Yan, Sanoff, Hanna K, Wang, Zefeng, Sharpless, Norman E

“…Human genome-wide association studies have linked single nucleotide polymorphisms (SNPs) on chromosome 9p21.3 near the INK4/ARF (CDKN2a/b) locus with…”
Get full text

A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer by Kim, Richard D., Sanoff, Hanna K., Poklepovic, Andrew S., Soares, Heloisa, Kim, Jongphil, Lyu, Jing, Liu, Yingmiao, Nixon, Andrew B., Kim, Dae Won

“…Background Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the…”
Get full text

Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer by MEYERHARDT, Jeffrey A, LING LI, SANOFF, Hanna K, CARPENTER IV, William, SCHRAG, Deborah

“…Clinical trials have shown that adding bevacizumab to cytotoxic chemotherapy improves survival for patients with colorectal cancer, although its effectiveness…”
Get full text

Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy by Cools, Katherine S., Sanoff, Hanna K., Kim, Hong Jin, Yeh, Jen Jen, Stitzenberg, Karyn B.

“…Background Surgical resection provides the only potentially curative treatment of pancreatic cancer. Neoadjuvant chemotherapy and/or radiation (NAT) is used to…”
Get full text

Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon Cancer Diagnosed After Age 75 Years by SANOFF, Hanna K, CARPENTER, William R, SCHYMURA, Maria J, SCHRAG, Deborah, STÜRMER, Til, GOLDBERG, Richard M, MARTIN, Christopher F, FINE, Jason P, JACKSON MCCLEARY, Nadine, MEYERHARDT, Jeffrey A, NILAND, Joyce, KAHN, Katherine L

“…Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group…”
Get full text

Qualitative evaluation of barriers and facilitators to hepatocellular carcinoma care in North Carolina by Ray, Emily M, Teal, Randall W, Carda-Auten, Jessica, Coffman, Erin, Sanoff, Hanna K

“…Many patients with hepatocellular carcinoma (HCC) never receive cancer-directed therapy. In order to tailor interventions to increase access to appropriate…”
Get full text

Practice Patterns and Long-Term Survival for Early-Stage Rectal Cancer by STITZENBERG, Karyn B, SANOFF, Hanna K, PENN, Dolly C, MEYERS, Michael O, TEPPER, Joel E

“…Standard of care treatment for most stage I rectal cancers is total mesorectal excision (TME). Given the morbidity associated with TME, local excision (LE) for…”
Get full text

INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis by Liu, Yan, Sanoff, Hanna K, Cho, Hyunsoon, Burd, Christin E, Torrice, Chad, Mohlke, Karen L, Ibrahim, Joseph G, Thomas, Nancy E, Sharpless, Norman E

“…Genome-wide association studies (GWAS) have linked common single nucleotide polymorphisms (SNPs) on chromosome 9p21 near the INK4/ARF (CDKN2A/B) tumor…”
Get full text

Five-Year Data and Prognostic Factor Analysis of Oxaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer: N9741 by SANOFF, Hanna K, SARGENT, Daniel J, CAMPBELL, Megan E, MORTON, Roscoe F, FUCHS, Charles S, RAMANATHAN, Ramesh K, WILLIAMSON, Stephen K, FINDLAY, Brian P, PITOT, Henry C, GOLDBERG, Richard M

“…In this report, we update survival (OS) and time-to-progression (TTP) data for the Intergroup trial N9741 after a median 5 years of follow-up by using…”
Get full text

Scoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma by Ritaccio, Gabrielle, Barritt Iv, A Sidney, Conklin, Jamie L, Richardson, Daniel R, Evon, Donna M, Sanoff, Hanna K, Basch, Ethan, Wheeler, Stephanie B, Moon, Andrew M

“…Treatment choices in hepatocellular carcinoma (HCC) involve consideration of tradeoffs between the benefits, toxicities, inconvenience, and costs. Stated…”
Get full text

A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors by Gbolahan, Olumide B., O’Neil, Bert H., McRee, Autumn J., Sanoff, Hanna K., Fallon, John K., Smith, Philip C., Ivanova, Anastasia, Moore, Dominic T., Dumond, Julie, Asher, Gary N.

“…Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both…”
Get full text

Improving Treatment Approaches for Rectal Cancer by Sanoff, Hanna K.

“…The cure rate for nonmetastatic rectal cancer has been improving for decades. Treatment for stage II and III rectal adenocarcinomas now routinely includes…”
Get full text

Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial by SANOFF, Hanna K, SARGENT, Daniel J, GREEN, Erin M, MCLEOD, Howard L, GOLDBERG, Richard M

“…Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy. A subgroup analysis of a…”
Get full text

PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer by Somasundaram, Ashwin, Sanoff, Hanna K

“…Neoadjuvant chemoradiotherapy has been a mainstay of the treatment of locally advanced rectal cancer. Programmed cell death protein 1 (PD-1) blockade therapy…”
Get more information

Cancer of unknown primary by Lee, Michael S, Sanoff, Hanna K

“…Cancers of unknown primary (CUPs) are histologically confirmed, metastatic malignancies with a primary tumor site that is unidentifiable on the basis of…”
Get more information

A Quantitative Model for Age-Dependent Expression of the p16INK4a Tumor Suppressor by Tsygankov, Denis, Liu, Yan, Sanoff, Hanna K., Sharpless, Norman E., Elston, Timothy C., Fraumeni, Joseph F.

“…Recent work has shown that expression of the $p16^{INK4a} $ tumor suppressor increases with chronological age. Expression is accelerated by gerontogenic…”
Get full text

Telemedicine for Cancer Care in the Time of COVID-19 by Royce, Trevor J, Sanoff, Hanna K, Rewari, Amar

Get more information

Best Evidence Supports Annual Surveillance for Resected Colorectal Cancer by Sanoff, Hanna K

“…Colorectal cancer is unique in solid tumor oncology because surgical resection for patients with solitary or oligometastatic disease can provide long-term…”
Get full text

Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease by Murphy, Caitlin C., Sanoff, Hanna K., Stitzenberg, Karyn B., Baron, John A., Lund, Jennifer L., Sandler, Robert S.

“…Background and Aims. As a first step toward understanding the increasing incidence of colorectal cancer (CRC) in younger (age < 50) populations, we examined…”
Get full text

Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer by Sanoff, Hanna K, Renfro, Lindsay A, Poonnen, Pradeep, Ambadwar, Pratibha, Sargent, Daniel J, Goldberg, Richard M, McLeod, Howard

“…Colorectal cancer (CRC) risk is partly conferred by common, low-penetrance single nucleotide polymorphisms (SNPs). We hypothesized that these SNPs are…”
Get full text